Stem cell therapeutics - ExCellThera

Drug Profile

Stem cell therapeutics - ExCellThera

Alternative Names: ECT 001; ECT 002; ECT 003; ECT 005; ECT-100; UM 171; UM171 + UM092; UM171 + UM390

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ExCellThera
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action CD34-antigen-stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma
  • Preclinical Immunological disorders

Most Recent Events

  • 07 Mar 2018 Phase-I/II clinical trials in Multiple myeloma (Late-stage disease, Second-line therapy or greater) in Canada (Parenteral) (NCT03441958)
  • 01 Mar 2018 Ciusss de L'Est de l'Île de Montréal and ExcellThera plans a phase I/II trial for Multiple-myeloma (Second line therapy or greater), in March 2018 (NCT03441958)
  • 01 Dec 2017 ECT 001 is available for licensing as of 01 Dec 2017. https://excellthera.ca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top